Live
- First Impressions and Unboxing of the MacBook Pro M4: A Powerhouse for Professionals and Creators
- China Gears Up for Potential Trade War Amid Trump’s Tariff Threats
- Small Farmers Gain Less by Selling to Supermarkets: Study Reveals
- Why Despite the Controversy, America Is Anticipating the Mike Tyson vs. Jake Paul Fight
- Sanju Samson and Tilak Varma Shine: Record-Breaking Feats in 4th T20I Against South Africa
- India Urges $1.3 Trillion Annual Climate Support for Developing Nations
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
Government mulls control, price cut of Medical Equipments
Highlights
A meeting of Committee of Secretaries, to discuss the mechanism for a separate price control order and a separate vertical within National Pharmaceutical Pricing Authority (NPPA) for medical devices, was held under the Chairmanship of Cabinet Secretary.
The Government is considering to control/reduce the prices of medical equipments like stent catheter and implants.
A meeting of Committee of Secretaries, to discuss the mechanism for a separate price control order and a separate vertical within National Pharmaceutical Pricing Authority (NPPA) for medical devices, was held under the Chairmanship of Cabinet Secretary. After deliberation, certain decisions were taken. In pursuance of the decision taken in the meeting, the Department of Pharmaceuticals had called a meeting with the representatives of various leading manufacturers of medical Devices. After detailed deliberations, the following decisions were taken:- (i) All manufacturers of stents/Implants will provide the information regarding ‘Price to retailer’ and ‘Maximum Retail Price’ in Form V appended to Drugs (Prices Control) Order, 2013, to NPPA positively by 30th Nov, 2015.
(ii) In the first week of December, the manufacturers will voluntarily propose a reduction in the marketing expenses of these products and consequentially on the MRP.
(iii) The Department of Pharmaceuticals may consider issuing a letter to the Industry Associations to consider voluntary disclosure and self-regulation of marketing expenses.
(iv) The self-regulation by the industry will be reviewed on the basis of information submitted by the industry to NPPA in Form V and a decision on statutory regulation will be taken subsequently.
This information was given by the Minister of State for Chemicals & Fertilizers, Shri Hansraj Gangaram Ahir in response to a question in the Lok Sabha today.
Next Story
ADVERTISEMENT
